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Abstract
Background: The cardiac sodium channel (Nav1.5) controls cardiac excitability. Accordingly, SCN5A mutations that result in
loss-of-function of Nav1.5 are associated with various inherited arrhythmia syndromes that revolve around reduced cardiac
excitability, most notably Brugada syndrome (BrS). Experimental studies have indicated that Nav1.5 interacts with the
cytoskeleton and may also be involved in maintaining structural integrity of the heart. We aimed to determine whether
clinical evidence may be obtained that Nav1.5 is involved in maintaining cardiac structural integrity.
Methods: Using cardiac magnetic resonance (CMR) imaging, we compared right ventricular (RV) and left ventricular (LV)
dimensions and ejection fractions between 40 BrS patients with SCN5A mutations (SCN5a-mut-positive) and 98 BrS patients
without SCN5A mutations (SCN5a-mut-negative). We also studied 18 age/sex-matched healthy volunteers.
Results: SCN5a-mut-positive patients had significantly larger end-diastolic and end-systolic RV and LV volumes, and lower
LV ejection fractions, than SCN5a-mut-negative patients or volunteers.
Conclusions: Loss-of-function SCN5A mutations are associated with dilatation and impairment in contractile function of
both ventricles that can be detected by CMR analysis.
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Introduction
The cardiac sodium channel, Nav1.5, controls cardiac excit-
ability by triggering the action potential of working cardiac
myocytes and driving electric impulse transmission. Its pore-
forming a-subunit is encoded by SCN5A. Accordingly, SCN5A
mutations that result in loss-of-function of Nav1.5 are associated
with various inherited arrhythmia syndromes that revolve around
reduced cardiac excitability (‘‘loss-of-function SCN5A channelo-
pathy’’) [1]. The most prevalent syndrome is Brugada syndrome
(BrS) [2]. More rarely, loss-of-function SCN5A mutations cause
progressive cardiac conduction disease [3], atrial standstill [4],
atrioventricular (AV) block [5], or sinus node disease [6]. It has
long been assumed that cardiac structural abnormalities are
undetectable by clinical imaging methods in individuals with loss-
of-function SCN5A channelopathies. This would be consistent with
the conventional concept that Nav1.5 is only involved in
maintaining electrical integrity of the heart. However, this
paradigm has been challenged by the recent discovery that
Nav1.5 may also be involved in maintaining structural integrity of
the heart. Although unexpected, such an involvement was
supported by experimental studies which have indicated that
Nav1.5 is part of a macromolecular complex that contains
cystoskeleton/cytoskeleton-associated proteins (reviewed in [7]).
Moreover, loss-of-function SCN5A mutations were found in rare
patients with dilated cardiomyopathy [8]. Still, clinical evidence to
link SCN5A mutations to structural derangements is anecdotal [9–
11], equivocal [12–13], or indirect [14–16]. For instance, while
one study showed histopathological derangements in myocardial
biopsies of BrS patients [12], the pathophysiologic role of these
derangements was questioned in another study [13]. Studies of
BrS patients that used cardiac magnetic resonance (CMR) imaging
[14–17] showed subtle abnormalities, including reduced contrac-
tile function of both right ventricle (RV) and left ventricle (LV),
and dilatation of the RV outflow tract (RVOT). Yet, these studies
were not designed to analyze whether such changes are related to
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the presence of SCN5A mutations, as they did not specifically
compare patients with SCN5A mutations to patients without
SCN5A mutations (BrS is also linked to other genes, and SCN5A
mutations, while playing an important role in BrS, are only found
in up to 25% of BrS patients [18]). Such an analysis would address
the question whether SCN5A variants per se cause structural cardiac
derangements.
With the aim of obtaining clinical evidence whether SCN5A is
involved in maintaining cardiac structural integrity, we systemat-
ically compared cardiac dimensions and contractility between 40
BrS patients with SCN5A mutations and 98 BrS patients without
SCN5A mutations using cardiac magnetic resonance imaging
(CMR).
Methods
This single-center study was conducted according to the
principles expressed in the Declaration of Helsinki. The Ethics
Committee of the Academic Medical Center Amsterdam ap-
proved this study. Written informed consent was obtained from all
patients and controls.
CMR Analysis
We studied 138 consecutive SCN5A genotyped BrS patients (57
probands) who had undergone CMR. We studied 3 groups: (1)
patients with SCN5A mutations (SCN5A-mut-positive, n = 40), (2)
patients without SCN5A mutations (SCN5A-mut-negative, n = 98),
(3) age/sex-matched healthy volunteers (n = 18). We used a 1.5
Tesla whole-body imaging system (Avanto, Siemens, Germany)
with a dedicated phased-array cardiac coil. The heart was
visualized in the standard long axis and short axis views, the
latter encompassing the total heart, using standard available steady
state free precession sequences. Scan parameters were: TR 1-2ms,
TE 2-4ms, Flip Angle 60–80u, slice thickness 6 mm, spatial
resolution in the x-y direction: 1–2 mm/pixel, temporal resolution
20–30 ms. To evaluate the presence of myocardial fatty infiltration
and edema, we acquired short axis double inversion T1 weighed
and T2 weighed, fat saturated black blood images, encompassing
the total heart (TR=RR interval, TE 40 ms, slice thickness
6 mm, interslice gap 2 mm, spatial resolution in the X-Y plane
$1 mm/pixel). After administration of intravenous Gadolinium
contrast, additional double inversion T1 weighed black blood
images with fat-suppression to assess late enhancement (as an
indicator of myocardial fibrosis) was acquired in the axial
direction. Images were acquired during repeated end-expiratory
breath-holds. Quantitative analysis was performed off-line using
dedicated commercially available software (MASS, Leiden, The
Netherlands). LV and RV end-systolic and end-diastolic images
were isolated in the stack of short axis CINE images and the
endocardial borders were delineated manually. From end-systolic
and end-diastolic LV and RV volumes, calculated by the modified
Simpson’s rule, stroke volumes and ejection fractions were derived.
Thickness of the LV posterior wall and anterior interventricular
septum (IVS) were measured on an end-diastolic short-axis slice
immediately basal to the tips of the papillary muscles. RVOT area
was measured at the level of the aortic valve on the axial black
blood images. Dimensions were corrected for body surface area
(BSA). All image analyses were performed by two experienced
observers who were blinded to the clinical history and results of
genetic screening.
Molecular Genetic Analysis
The entire coding region of SCN5A was analyzed as described
previously [19]. Truncating mutations were defined as those in
which a premature stop codon was present or caused by a
frameshift. In all SCN5A-mut-negative patients, we also screened
SCN1B and GPD1-L, but found no mutations.
Statistical Analysis
Data are mean6SD. Two-tailed t-test was performed to
compare group means, Chi-square test to compare proportions.
Linear regression analysis was performed to study the relation
between ECG parameters (heart rate, PR duration, QRS
duration) and cardiac dimensions. Linear regression analysis was
also performed to compare CMR data between patient groups,
thereby correcting for sex and presence of coronary artery disease.
p,0.05 was considered statistically significant.
Results
Demographic and ECG Data
Demographic data were not different between groups (Table 1).
Consistent with our previous study [20], SCN5A-mut-positive
patients had evidence of generally slower conduction than SCN5A-
mut-negative patients, i.e., longer electrocardiographic PR and
QRS intervals. No patient had right or left bundle branch block.
Qualitative CMR Analysis
Only few patients had some evidence for myocardial fibrosis or
fatty infiltration, and the proportion of such patients did not differ
statistically significantly between the groups: fibrosis in 3 of 40
SCN5A-mut-positive and 3 of 98 SCN5A-mut-negative patients
(p = 0.1); fatty infiltration in 1 of 40 SCN5A-mut-positive and 2 of
98 SCN5A-mut-negative patients (p = 0.9). No patient had
evidence for myocardial edema.
Quantitative CMR Analysis
Right ventricle. SCN5A-mut-positive patients had larger RV
dimensions than subjects without SCN5A mutations (SCN5A-mut-
negative patients or volunteers), as evidenced by larger RV end-
systolic and end-diastolic volumes. Moreover, their RV ejection
fractions were lower, albeit still in the normal range, than in
volunteers (Table 2). In contrast, RVOT areas were significantly
larger in both patient groups (SCN5A-mut-positive or SCN5A-mut-
negative) than in volunteers. All other RV dimensions were similar
between the 3 groups.
Left ventricle. SCN5A-mut-positive patients also had larger
LV end-systolic volumes and lower (within the normal range) LV
ejection fractions than subjects without SCN5A mutations (SCN5A-
mut-negative patients or volunteers, Table 2). All other LV
dimensions were similar between the 3 groups.
Correlation between CMR Changes and Severity of
Reduction in Nav1.5 Current
Having found that SCN5A mutations are associated with
changes in ventricular dimensions and contractility, we studied
whether the severity of CMR changes correlated with the severity
of reduction in Nav1.5 current. As a measure of such reduction, we
used the magnitude of PR or QRS prolongation. We found that
PR and QRS width correlated statistically significantly with end-
systolic volumes of RV and LV (Table 3). We also studied whether
RV/LV dimensions and ejection fractions were lower in SCN5A-
mut-positive patients with truncating SCN5A mutations (more
reduction in Nav1.5 current predicted, n= 7) than in those with
missense SCN5A mutations (less reduction in Nav1.5 current
predicted, n= 33). Although RV and LV ejection fractions tended
to be lower in the small group of patients with truncating
SCN5A and Cardiac Dimensions
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mutations than in patients with missense mutations, these
differences did not reach statistical significance (Table 4). Finally,
we conducted a subanalysis in the 2 patients in this cohort (2 men,
aged 25 and 38 years) who were compound heterozygous carriers
of a SCN5A mutation. These patients appeared to have, on
average, more RV and LV dilatation (RVEDV/BSA 107.560.9,
RVESV/BSA 60.065.7, LVEDV/BSA 99.461.6, LVESV/BSA
50.063.7) and more reduced RVEF and LVEF (RVEF 44.165.8,
LVEF 49.764.5) than patients with a single SCN5A mutation.
Because these were only 2 patients, we conducted no statistical
analysis to test for differences with patients with a single SCN5A
mutation.
Analysis of Possible Confounders
We studied the possible role of confounders for RV/LV
contractile function. First, we studied for differences in the
prevalence of a spontaneous type-1 pattern on the baseline ECG
[21]. Among SCN5A-mut-positive patients, 10 had a spontaneous
type-1 pattern on the baseline ECG, while 30 had a type-1 pattern
only after ajmaline testing. These numbers were 7 and 91,
respectively, for SCN5A-mut-negative patients (the number of
ECGs per patient were 7.364.6 and 7.464.4 among SCN5A-mut-
positive and SCN5A-mut-negative patients, respectively). The
proportion of patients with a spontaneous type-1 pattern was
statistically significantly higher among SCN5A-mut-positive pa-
tients (p = 0.004). It is conceivable that the higher proportion of
such patients may indicate that SCN5A-mut-positive patients were
more severely affected, and that this may (partly) explain the
difference in RV and LV dimensions between SCN5A-mut-positive
and SCN5A-mut-negative patients [15]. Yet, patients with a
spontaneous type-1 pattern were not statistically significantly
different from patients with a type-1 pattern only after ajmaline
testing with regards to RVEDV, RVESV, LVEDV or LVESV.
The prevalences of hypertension or diabetes were not statisti-
cally significantly different between SCN5A-mut-positive patients
(hypertension: 5/40, diabetes: 1/40) and SCN5A-mut-negative
patients (hypertension: 14/98 [p= 0.8 vs. 5/40], diabetes: 5/98
[p= 0.5 vs. 1/40]). The prevalence of coronary artery disease was
statistically significantly higher among SCN5A-mut-positive pa-
tients (4/40) than among SCN5A-mut-negative patients (1/98
[p= 0.01]). Yet, it is unlikely that the higher proportion of patients
with coronary artery disease explained the higher values of
RVEDV, RVESV, LVEDV or LVESV observed among SCN5A-
mut-positive patients, because we corrected for the presence of
coronary artery disease (and sex) when we compared these
measures between the groups. Moreover, the average values for
RVEDV, RVESV, LVEDV, and LVESV did not differ statisti-
cally significantly between patients with coronary artery disease
and those without.
Heart rates of SCN5A-mut-positive patients were statistically
significantly lower than in SCN5A-mut-negative patients during
cardiac MRI examination (66.3610.8 vs. 72.3611.9 beats per
minute, p = 0.007). Longer diastolic filling times may have
contributed in part to larger end-diastolic volumes of RV and
LV in SCN5A-mut-positive patients. Indeed, we found that cycle
length correlated statistically significantly with RVEDV/BSA
(p= 0.002), RVESV/BSA (p= 0.003), LVEDV/BSA (p= 0.001),
and LVESV/BSA (p= 0.02) (but not with RVEF [p= 0.2] or
LVEF [p= 0.9]). Yet, these correlations were only weak (correla-
tion coefficients were 0.27, 0.25, 0.28, and 0.20, respectively),
suggesting that this is not the only factor to explain differences in
RV and LV dimensions between SCN5A-mut-positive and SCN5A-
mut-negative patients.
Discussion
We found that BrS patients with an SCN5A mutation have
enlargement of both RV and LV, compared with persons without
an SCN5A mutation (SCN5A-mut-negative BrS patients or
volunteers). The severity of RV/LV enlargement correlated with
the magnitude of reduction in Nav1.5 current, suggesting a
causative role of reduction in Nav1.5 current. However, this
correlation was not strong. Previous studies add further evidence
to the notion that Nav1.5 current reduction alone is not sufficient
to cause structural changes in RV and LV. For instance, rats and
mice with chronically reduced Nav1.5 current secondary to long-
term (18–24 months) treatment with flecainide, a cardiac
antiarrhythmic drug that blocks Nav1.5 current, did not develop
Table 1. Demographic and ECG data.
SCN5A positive
(n=40)
SCN5A negative
(n=98)
Volunteers
(n =18)
P value* SCN5A positive vs.
SCN5A negative
Age, years 45.1614.3 43.9612.5 42.068.7 0.77
Sex, man/woman (n) 22/18 49/49 8/10 0.46
Type of SCN5A mutation,
missense/truncation (n)
33/7
ECG parameters
Heart rate, beats per min 64.7610.1 68.8611.0 0.049
PR, ms 192.2630.5 162.3623.4 ,0.001
QRS, ms 110.7615.2 100.7611.7 ,0.001
QT, ms 383.9626.5 365.3630.7 0.001
QTc, ms 396.3628.3 387.9624.2 0.09
S duration in II, ms 41.2627.2 35.2619.8 0.16
S amplitude in II, mV 0.2360.23 0.1960.15 0.23
S duration in III, ms 33.5632.0 34.3626.0 0.88
S amplitude in III, mV 0.1860.24 0.2160.26 0.46
*P value calculated with two-tailed t-test.
doi:10.1371/journal.pone.0042037.t001
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cardiac fibrosis [22]. Thus, the presence of abnormal Nav1.5
proteins per se in our SCN5A-mut-positive patients may have
contributed to the increases in cardiac dimensions and reductions
in contractility. This finding would support the recent proposal
that Nav1.5 is involved in maintaining structural integrity of the
heart. This proposal is supported by various transgenic mouse
studies in which SCN5A was mutated to recapitulate loss-of-
function SCN5A channelopathy exhibited age-dependent degen-
erative histopathologic changes, including fibrosis and fatty
replacement [23–24].
Nav1.5 is a transmembrane protein composed of the main pore-
forming a-subunit and two subsidiary b-subunits (b1 and b2) [1].
There is accumulating evidence that Nav1.5 forms part of a
macromolecular complex [7] and that its function is modulated by
cytoskeleton proteins, e.g., tubulin [25], syntrophin, and dystro-
phin [26–27]. Given these interactions between Nav1.5 and
cytoskeleton proteins, it is conceivable that, conversely, abnormal
Nav1.5 proteins affect cytoskeleton function and structural
integrity of cardiomyocytes. Yet, this proposal awaits experimental
evidence.
While we found that ejection fractions of RV and LV were
lower in carriers of a SCN5A mutation than in non-carriers,
RVOT diameters were similarly increased in SCN5A-mut-positive
and SCN5A-mut-negative patients. This finding indicates that
structural derangement of RV is a common feature of BrS. RV
may be more susceptible than LV to stressors that disrupt
structural integrity. Support for this notion comes from the
observation that fibrosis was largest in RV, in particular, RVOT,
in control hearts. The biological basis of these observations is a
matter of speculation. It may lie in fundamental differences in gene
expression profiles between RV and LV that can be traced to
embryologic development of the heart [28]. Thus, electrical and
mechanical properties of RV and LV are intrinsically different,
and genetic and environmental stressors may act differently in RV
and LV. Importantly, SCN5A expression is higher in RV than in
LV [29]. Thus, if Nav1.5 contributes to cytokeleton integrity of the
heart, loss-of-function SCN5A channelopathy is expected to affect
RV more strongly than LV. Still, we obtained evidence that the
pathophysiologic derangements in BrS are not confined to RV, as
long assumed, but that LV is also significantly affected, as recently
reported [15]. The observation that BrS affects both ventricles,
and that RVOT dilatation is a feature shared by all BrS patients,
regardless of the presence of a SCN5A mutation, may be taken as
supportive evidence for the notion that BrS should be considered a
cardiomyopathy with predominant but not exclusive involvement
of RV, similar to arrhythmogenic right ventricular cardiomyop-
athy. Moreover, it suggests that the disease-causing genes in BrS
patients who have no SCN5A mutation are also involved in
structural integrity of the heart, similar to SCN5A. One explana-
tion could be that the protein products of these genes (most of
which await discovery) also interact with the cytoskeleton, possibly
through their interaction with SCN5A. Indeed, some known genes
that are involved in BrS (although rarely) interact with SCN5A,
notably SCN1B [30] and GPD1-L [31]. It is conceivable that the
SCN5A-mut-negative BrS patients in our study carried mutations
in such genes (but not in SCN1B and GPD1-L, which were
screened), and that the presence of these mutations explained, at
least in part, why SCN5A-mut-positive patients differed far less
from SCN5A-mut-negative patients than from controls with
regards to CMR parameters. Similarly, the differences between
SCN5A-mut-positive and SCN5A-mut-negative patients were only
statistically significant for RVEDV, RVESV, LVESV, and LVEF,
and we observed no differences in the incidence of fibrosis or fatty
infiltration between both groups. While the lack of statistical
significance for fibrosis or fatty infiltration may indicate a lack of
statistical power in our study, it is to be expected that differences
between SCN5A-mut-positive and SCN5A-mut-negative patients
are relatively small, and that other parameters for structural
properties are not different between both groups, given the fact
that Brugada syndrome is generally regarded a primary electrical
disease, i.e., a disease in which gross structural changes cannot be
routinely detected with current cardiac imaging methods.
Table 3. Correlation between electrocardiographic PR and
QRS width and end-systolic volumes of RV and LV.
correlation
coefficient, R P value*
PR vs. RVESV 0.21 0.014
QRS vs. RVESV 0.24 0.006
PR vs. LVESV 0.25 0.005
QRS vs. LVESV 0.26 0.003
LVESV, left ventricular end-systolic volume; RVESV, right ventricular end-systolic
volume.
*P value calculated with linear regression analysis.
doi:10.1371/journal.pone.0042037.t003
Table 4. RV/LV dimensions and ejection fractions in patients with truncating SCN5A mutations and missense SCN5A mutations.
truncating mutation (n=7) missense mutation (n=33) P value*
Age, years 43.0621.2 45.5612.8 0.06
Sex, man/woman (n) 3/4 19/14 0.48
RVEDV/BSA, ml/m2 85.4610.9 88.5615.1 0.61
RVESV/BSA, ml/m2 44.469.6 42.5611.4 0.68
RVEF, % 48.765.3 52.766.0 0.11
LVEDV/BSA, ml/m2 78.4622.7 84.3614.8 0.39
LVESV/BSA, ml/m2 35.468.7 38.069.6 0.51
LVEF, % 53.268.7 55.266.0 0.46
LVEDV/BSA, left ventricular end-diastolic volume corrected for body surface area; LVEF, left ventricular ejection fraction; LVESV/BSA, left ventricular end-systolic volume
corrected for body surface area; RVEDV/BSA, right ventricular end-diastolic volume corrected for body surface area; RVEF, right ventricular ejection fraction; RVESV/BSA,
right ventricular end-systolic volume corrected for body surface area.
*P value calculated with two-tailed t-test.
doi:10.1371/journal.pone.0042037.t004
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Our findings of larger RV dimensions, reduced contractile
function of both RV and LV, and larger RVOT areas in BrS
patients are in accordance with previous studies [14–17].
However, some of our values (e.g., RVEDV and LVEDV) are
different from those studies. Since our values of end-diastolic
volumes, end-systolic volumes, and ejection fractions of LV and
RV are within the range of published normalized data [32], we
believe that these differences can be mainly attributed to
methodological differences (e.g., determining which basal slice to
include in the analysis). Of importance, we included our own
cohort of healthy volunteers in which the analysis was done in the
same way as in the patients.
While we found that SCN5A-mut-positive BrS have reduced
ejection fractions, previous studies have indicated that BrS patients
also have slow conduction of the cardiac electrical impulse,
notably in RV [33–34]. We cannot rule out that conduction
slowing may have resulted in loss of contractile synchrony between
various regions of the heart [35], and that this may have
contributed partly to reduced ejection fractions. In any case,
patients with right or left bundle branch block were not included
in the present analysis.
Moreover, we found that QRS (and PR) width correlated with
end-systolic volumes of RV and LV. Yet, it must be noted that
QRS width per se may not reflect solely sodium channel
malfunction/deficiency, but that it may also be caused by other
factors, e.g., nonsynchronous activation. Clearly, ECG analysis
alone cannot distinguish between the effects of each of these (and
possibly other) factors. Still, nonsynchronous activation may be an
important factor that may adversely affect RV and LV hemody-
namics. This has been clearly shown in numerous studies that
demonstrated the beneficial effects of cardiac resynchronization
therapy for patients with left ventricular failure which is associated
with dyssynchronous activation of parts of the LV [36]. However,
in the case of BrS, a disease that predominantly affects the RV,
dyssynchrony is more likely to relate to later activation of RV with
respect to LV, rather than between various parts of LV [35].
Moreover, we recently showed not only that, in RV disease, RV
activation is delayed with respect to LV activation, and that this
delay is associated with adverse hemodynamic effects, but also that
these adverse effects can be corrected by resynchronization
(pacing) of RV [37].
Limitations
Cardiac dilatation and reduced contractility may be due to
histologic changes (fibrosis, fatty degeneration), as recently
reported [12]. However, we found virtually no signs for these
abnormalities. It is probable that the spatial resolution of current
clinical imaging methods, such as CMR, is too low to detect such
changes; this would explain why BrS has been classified a primary
electrical disease, and it has taken long before it was recognized
that structural derangements are also present. We expect that the
ability to study larger cohorts or use new imaging techniques may
unmask differences in the incidence of histopathologic abnormal-
ities between SCN5A-mut-positive and SCN5A-mut-negative pa-
tients and/or between BrS patients and non-BrS patients. It is
conceivable that such an ability may have immediate clinical
implications, e.g., for risk stratification. For instance, studies are
now emerging which clearly demonstrate that areas of fibrosis are
crucially linked to the occurrence/inducibility of reentrant
arrhythmias, including ventricular fibrillation, in BrS patients
[9–10,38].
While this study focused on a possible role of Nav1.5 in
determining RV and LV dimensions and contractility, it is
conceivable that other sarcolemmal ion channels involved in BrS,
e.g., L-type calcium channels may also play a role; the L-type
calcium channel encoding genes implicated in BrS [39] were,
however, not screened.
Conclusions
Loss-of-function SCN5A mutations are associated with dilatation
and impairment in contractile function of both ventricles that can
be detected by CMR analysis. These findings support the notion
that Nav1.5 is involved in maintaining structural integrity of the
heart.
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